Hepatocellular carcinoma (HCC) is the third most common ... This review outlines the epidemiological trends, risk factors, diagnostic developments and novel therapeutics for HCC, both in the ...

Disparities in liver cancer risk and outcomes in the LGBTQ community: A literature review. Non-contrast MRI as a surveillance tool for recurrent hepatocellular carcinoma after curative treatment: A ...

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...

Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.

A new study in the peer-reviewed Journal of Interferon & Cytokine Research (JICR) showed that a specific retinoic ...

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today presented positive, final data from the ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Announcing a new publication for Acta Materia Medica journal. Icaritin (ICA) is a prenylflavonoid natural product extracted from plants of the Epimedium genus.

BRISBANE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology ...

Worldwide, hepatitis B virus is the major risk factor for hepatocellular carcinoma (HCC), owing to its high prevalence in the developing world. Hepatitis B virus vaccination programs have and will ...